Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996447 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
A Phase 3 study of Blood Brain Barrier Defect and CNS Lesion, sponsored by Guerbet.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT03996447 is a Phase 3 study of Blood Brain Barrier Defect and CNS Lesion that has completed, run by Guerbet. The registered enrollment target is 260 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT03996447, a Phase 3 study of Blood Brain Barrier Defect and CNS Lesion, has completed, sponsored by Guerbet.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial aimed to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Conditions Studied
Interventions
- DRUG gadopiclenol
- DRUG Gadobutrol 1Mmol/mL Solution for Injection Vial
Study Locations (20)
Other
- ZNA Middelheim - Antwerp
- UZ Brussel - Campus Jette - Brussels
- CHRU - Hôpital Roger Salengro - Neurologie - Lille
- Centre Hospitalier Sainte-Anne - Paris
- CHU La Miletrie - Poitiers
- CHRU Strasbourg Hôpital de Hautepierre - Strasbourg
- Uniklinik Mannheim - Mannheim
- Semmelweis Egyetem - Neurology - Budapest
- Orszagos Klinikai Idegtudomanyi Intezet - Budapest
- Debreceni Egyetem Klinikai Kozpont - Debrecen
- Pecsi Tudomanyegyetem Klinikai Kozpont - Idegsebeszeti Klinika - Pécs
- Szegedi Tudomanyegyetem AOK - Szeged
Illinois
- Northwestern Memorial Hospital - Chicago
- Northwest Neurology, Ltd. - Rolling Meadows
California
- ASCLEPES Research Centers - Panorama City
Connecticut
- University of Connecticut Health Center - Farmington
Missouri
- University of Missouri Hospital and Clinic - Columbia
Pennsylvania
- University Of Pennsylvania - Philadelphia
South Carolina
- South Carolina Clinical & Translational Research (SCTR) Institute - Charleston
Washington
- University Of Washington - Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2020-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03996447
The ClinicalTrials.gov registry entry for NCT03996447 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Guerbet, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Blood Brain Barrier Defect appearing as the primary indexed condition, and to 2 interventions - of which gadopiclenol is the first listed.
NCT03996447 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT03996447 about?
NCT03996447 is a clinical study titled "Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)". This trial aimed to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
What is the current status of trial NCT03996447?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2019-06-03. Estimated completion is 2020-09-11.
What conditions does trial NCT03996447 study?
This clinical trial studies the following conditions: Blood Brain Barrier Defect, CNS Lesion.
What interventions are being tested in trial NCT03996447?
The interventions under investigation include: gadopiclenol (DRUG), Gadobutrol 1Mmol/mL Solution for Injection Vial (DRUG).
Who is sponsoring clinical trial NCT03996447?
This trial is sponsored by Guerbet, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03996447 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Brain Barrier Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.